Adaptive Biotechnologies (NASDAQ:ADPT) COO Julie Rubinstein Sells 141,583 Shares of Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) COO Julie Rubinstein sold 141,583 shares of the firm’s stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $13.29, for a total value of $1,881,638.07. Following the transaction, the chief operating officer owned 516,610 shares of the company’s stock, valued at $6,865,746.90. The trade was a 21.51% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Julie Rubinstein also recently made the following trade(s):

• On Friday, March 13th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $12.96, for a total transaction of $247,017.60.
• On Monday, March 9th, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.79, for a total transaction of $457,617.39.
• On Tuesday, March 10th, Julie Rubinstein sold 19,460 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.68, for a total transaction of $285,672.80.
• On Tuesday, March 3rd, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $15.67, for a total transaction of $484,845.47.
• On Thursday, March 5th, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $16.00, for a total transaction of $495,056.00.

Adaptive Biotechnologies Stock Up 5.8%

NASDAQ:ADPT opened at $13.17 on Friday. The stock has a market cap of $2.03 billion, a price-to-earnings ratio of -32.92 and a beta of 2.19. The company’s 50 day moving average price is $16.55 and its 200-day moving average price is $15.85. Adaptive Biotechnologies Corporation has a 52 week low of $6.68 and a 52 week high of $20.76.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its quarterly earnings data on Thursday, February 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.10. Adaptive Biotechnologies had a negative return on equity of 46.68% and a negative net margin of 21.48%.The business had revenue of $71.68 million for the quarter, compared to analysts’ expectations of $59.38 million. During the same period in the prior year, the firm posted ($0.23) EPS. The firm’s quarterly revenue was up 51.0% on a year-over-year basis. As a group, sell-side analysts anticipate that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Wednesday, January 21st. BTIG Research raised their price target on shares of Adaptive Biotechnologies from $21.00 to $22.00 and gave the company a “buy” rating in a report on Friday, February 6th. Morgan Stanley started coverage on shares of Adaptive Biotechnologies in a report on Monday, December 1st. They set an “equal weight” rating and a $21.00 price objective for the company. Wall Street Zen downgraded shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Finally, Guggenheim lifted their target price on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $18.25.

Key Stories Impacting Adaptive Biotechnologies

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Recent fundamental backdrop: Adaptive’s Feb. 5 quarterly report showed an EPS beat and revenue that was up ~51% year-over-year, supporting investor confidence heading into March. MarketBeat ADPT profile
• Neutral Sentiment: Short-interest print for March shows 0 shares and NaN changes (likely a reporting error). That data point provides no clear bearish signal and may have contributed to lower perceived short pressure. (No reliable short-interest signal.)
• Negative Sentiment: Significant insider selling on Mar. 11–13: combined, company executives and insiders sold roughly 1.25M shares for about $16.6M in proceeds, materially reducing several insiders’ stakes (examples below). This coordinated selling can be perceived negatively by investors as supply into the market or insiders taking liquidity. Filings: CEO Chad M. Robins (470,167 sh, ~$6.19M) Chad Robins Form 4; Harlan S. Robins (470,266 sh, ~$6.19M) Harlan Robins Form 4; COO Julie Rubinstein (160,643 sh across filings) Julie Rubinstein Form 4; CFO Kyle Piskel (18,672 sh) Kyle Piskel Form 4; Sharon Benzeno (63,103 sh) Sharon Benzeno Form 4; Susan Bobulsky (41,338 sh) Susan Bobulsky Form 4; Francis Lo (30,593 sh) Francis Lo Form 4.

Institutional Trading of Adaptive Biotechnologies

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. AQR Capital Management LLC raised its position in Adaptive Biotechnologies by 45.8% in the first quarter. AQR Capital Management LLC now owns 310,272 shares of the company’s stock worth $2,265,000 after acquiring an additional 97,444 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Adaptive Biotechnologies by 4.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 68,830 shares of the company’s stock valued at $511,000 after acquiring an additional 2,914 shares during the period. Caxton Associates LLP purchased a new stake in shares of Adaptive Biotechnologies in the 1st quarter worth $93,000. Envestnet Asset Management Inc. purchased a new stake in shares of Adaptive Biotechnologies in the 2nd quarter worth $467,000. Finally, Savant Capital LLC raised its holdings in Adaptive Biotechnologies by 15.4% in the 2nd quarter. Savant Capital LLC now owns 39,665 shares of the company’s stock worth $462,000 after purchasing an additional 5,305 shares during the period. 99.17% of the stock is owned by hedge funds and other institutional investors.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.